SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By:

Slides:



Advertisements
Similar presentations
Establishment of National SPS Notification Authority & National Enquiry Point Saudi Arabian Experience Transparency Workshop Geneva - October 2010.
Advertisements

Prequalification of HIV/AIDS Drugs - UN joint activity lPartners* –UNAIDS –UNICEF –UNFPA –WHO –With the support of World Bank lWHO –Manages, provides technical.
Biopharmaceutical Quality
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
World Health Organization
BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Prequalification and Quality Monitoring of anti-malaria products Andre van Zyl, M. Pharm. Project Manager Health Technology and Pharmaceuticals Cluster,
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
WHO Good Governance for Medicines programme Technical Briefing Seminar 19 November 2009, Geneva Dr Guitelle Baghdadi-Sabeti Department of Essential Medicines.
Introduction to PPDs Regulatory requirements and rationale.
1 Current Issues for Conduction of BE Studies in Pakistan 1 st Symposium on Bioequivalence and Bioavailability Studies April 2014, Lahore, Pakistan.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
VALIDATION OF RAW MATERIALS
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Validation of Analytical Methods Used For Bioequivalence.
Structure of Dossier of Medicinal Product- Q part
FDA Nasal BA/BE Guidance Overview
Overview of Medical Devices Sector Saudi Food and Drug Authority (Saudi Arabia) Dr. Saleh Al Tayyar Director General Medical Devices Sector Saudi Food.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk
Registration in lebanon
Regulatory Overview.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Bioequivalence and Bioavailability Working Group.
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
Topics discussed in the presentation
Important informations
ACCESS TO MEDICINES - POLICY AND ISSUES
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
WHO Prequalification Programme of Medicines: Experience Working with Manufacturers and Regulators in the WHO Eastern Mediterranean Region Mohamed Abdelhakim.
Overview of FDA's Regulatory Framework for PET Drugs
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice &
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
API’s Registration Process supported by Apteka-95 Pharmaceutical Firm, Ltd. API’s Registration Process supported by Apteka-95 Pharmaceutical Firm, Ltd.
TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Draft Law of Kyrgyz Republic on Medicinal Products Syrdybaev Suyunbek, Head of expert group of ISWG of MoH KR 4 th Forum of МеТА Kyrgyz Republic Bishkek,
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.
Laura Gomes Castanheira ANVISA- Brazil Implementation of bioequivalent medicines regulation.
Veterinary Products Management and Quality Control System in Thailand : Veterinary Vaccine Tasanee Lorchaivej Workshop on the Veterinary Products.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
We, COSMETICS REGISTRATION (INDIA) are a consultancy subsidiary of ARHAM CONSULTANTS (INDIA) PTY, New Delhi and are focused on the regulatory compliance.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Jordan Food & Drug Administration Administration.
ROLES AND RESPONSIBILITIES OF TFDA ON ADDO PROGRAM
CTD Content Management
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.
Saudi Arabia: Veterinary Pharmaceutical Legislations &
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
GMP Legal Framework in Kyrgyzstan
Presentation transcript:

SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies of Generic Pharmaceutical Products Workshop-Day II Introduction and workshop Objectives By: Saleh A. Al-Suwayeh, M.Sc., Ph.D. Associate Professor of Pharmaceutics, College of Pharmacy, King Saud University & Chairman of the Technical Registration Committee at the Saudi MOH

SFDA-2007 الهيئة العامة للغذاء والدواء General Outline I. Introduction and Background:  The transitional state between the Saudi MOH and the Saudi FDA.  Bioequivalence studies as essential part of the registration dossier.  SFDA future expectations. II. Bioequivalence Workshop Objectives III. Conclusions 

SFDA-2007 الهيئة العامة للغذاء والدواء I. Introduction and Background: The transitional state between the Saudi MOH and the Saudi FDA:  In the past 30 years, the Saudi MOH was responsible for regulating pharm. products and manufactures.  The Saudi FDA was Founded in 2003 based on the Royal Decree # 1 dated 7/1/1424 AH.  Independent Regulatory Body Directly Supervised by the Supreme Council of Ministers. - Establishment Phase Extends over a 5 Year Period.  One of its prime duties is to assume regulatory responsibility of pharmaceutical products and manufactures from MOH. 

SFDA-2007 الهيئة العامة للغذاء والدواء Bioequivalence Studies as Essential Part of the Registration Dossier.  Table of Contents of the Dossier  Signed Registration Form  Composition and Methods of Analysis  Stability Studies  Certificate of Analysis of the Finished Product  Free Sale Certificate / CPP  Package Insert  Product Samples in Final Form  List of Countries where Product is Registered and Marketed  Clinical Studies (efficacy, safety, toxicology, pharmacology … etc.)  Bioavailability or Bioequivalence Studies  PMS Studies.

SFDA-2007 الهيئة العامة للغذاء والدواء SFDA Future Expectations 1) To provide Written published Laws and Guidelines such as:  Current GMP Guidelines  Stability Guidelines  Bioequivalence studies Guidelines  Rules of Co-manufacturing  Rules of Resourcing  Pricing Guidelines and other guidelines. - Guidelines can provide information that enhance safety, reliability and performance of services - Guidelines provide reference criteria that a process or service must meet - The culmination of mandatory guidelines is intended to be improved public health. 2) To reduce Shortage of Staff and Reduce Turnover Rate of Personnel 3)To provide proper training of personnel via symposia and workshops e.g., this current bioequivalence workshop.

SFDA-2007 الهيئة العامة للغذاء والدواء II. Bioequivalence Workshop Objectives So far in day 1 and this morning, many theoretical basis were discussed to lay down foundation for today ’ s practical experience. These theoretical basis essentially included:  An overview of the SFDA Bioequivalence guidelines.  Bioanalytical methodology and validation  Statistical analysis and acceptance criteria  More emphasis on special consideration for some drugs ( long t1/2 drugs …..etc.)  A special topic on the regulatory guidelines for biosimilars.  Inspection of bioequivalence centers and analytical laboratories.

SFDA-2007 الهيئة العامة للغذاء والدواء II. Bioequivalence Workshop Objectives Objctives of Day 2: 1) To familiarize participants with other important theoretical basis as preparation for the practical experience. These theoretical basis will essentially include  Contents of Bioequivalence report.  Evaluation forms and check lists  How to evaluate Bioequivalence report 2) To provide participants with hands-on practical experience of bioequivalence report dealing with different issues of bioequivalency such as:  Bioanalytical section of Bioequivalence study  Statistical report of Bioequivalence study  PK parameters essential in a Bioequivalence study  A good and a poor example of Bioequivalence studies will be presented.

SFDA-2007 الهيئة العامة للغذاء والدواء III. Conclusion With the newly founded independent Saudi FDA and with updated published guidelines and well trained personnel, we are very optimistic that the process of registration will be more efficient in terms of time and effort leading consequently to a positive impact on the health of the public. “ GOOD LUCK ”